
=> file reg FILE 'REGISTRY' ENTERED AT 15:53:46 ON 09 DEC 94 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1994 American Chemical Society (ACS)

٢

STRUCTURE FILE UPDATES: 02 DEC 94 HIGHEST RN 159344-42-0 DICTIONARY FILE UPDATES: 08 DEC 94 HIGHEST RN 159344-42-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 1994

Please note that search-term pricing does apply when conducting SmartSELECT searches.



NODE ATTRIBUTES: CONNECT IS E1 RC AT 15 DEFAULT MLEVEL IS ATOM MLEVEL IS CLASS AT 7 8 9 10 11 **GGCAT** IS UNS AT 29 DEFAULT ECLEVEL IS LIMITED ECOUNT IS UNLIMITED AT 8 9 10 11 7

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

```
L5
    file hca
=>
```

87 SEA FILE=REGISTRY SSS FUL L3

FILE 'HCA' ENTERED AT 15:55:33 ON 09 DEC 94 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1994 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 26 Nov 1994 (941126/ED) VOL 121 ISS 22

=> d his 16

(FILE 'REGISTRY' ENTERED AT 15:49:31 ON 09 DEC 94) SAVE L5 TRIN162/A

6 CA ref 1s from the 87 structure ENTERED AT 15:51:47 ON 09 DEC 94 FILE 'HOW L6 6 S L5

=> d 16 1-6 all

L6 ANSWER 1 OF 6 HCA COPYRIGHT 1994 ACS

AN 121:109331 HCA

TI Preparation of fluorotaxols as antitumor agents

IN Chen, Shu Hui; Farina, Vittorio; Kant, Joydeep; Vyas, Dolatrai M.

PA Bristol-Myers Squibb Co., USA

SO U.S., 21 pp. Cont.-in-part of U.S. Ser. No. 6,423, abandoned. CODEN: USXXAM

PΙ US 5294637 A 940315

AΙ US 93-62687 930520

PRAI US 92-907261 920701

US 92-996455 921224

US 93-6423 930119

US 93-29819 930311

DT Patent

LA English

IC ICM A01N043-02

ICS C07D305-00

NCL 514449000

CC 30-20 (Terpenes and Terpenoids)

Section cross-reference(s): 1


os MARPAT 121:109331

GΙ

Ι

```
AB
     Title compds. [I; R1 = COR, CO2R; R = (cyclo)alkyl, alkenyl, Ph,
     etc.; R2 = H, OH, OR, O2CR, etc.; R3 = (cyclo)alkyl, alkenyl, WR4,
     etc.; R4 = Ph, naphthyl, furyl, thienyl, etc.; W = bond, alkenylene,
     (CH2)1-6] were prepd. Thus, taxol was converted to
     N-debenzoyl-N-tert-butoxycarbonyl-7.alpha.-fluorotaxol which gave
     mean survival time 147% of controls in M109 lung carcinoma
     inoculated-mice receiving 40mg/kg i.p. on days 5 and 8 post-implant.
ST
     fluorotaxol prepn antitumor agent; taxol fluoro prepn antitumor
     agent
IT
     Neoplasm inhibitors
        (fluorotaxols)
IT 150799-82-9P 150799-84-1P 156294-33-6P
   156294-35-8P 156294-36-9P
        (formation of, in prepn. of antitumor agent)
IT
     92-29-5P, Hydrobenzamide 132127-34-5P
                                               133066-59-8P
     144764-08-9P
                    144764-09-0P
                                   144790-00-1P
                                                  144790-01-2P
                                   148121-25-9P
                                                   148121-26-0P
     147650-53-1P
                    148121-24-8P
     148205-41-8P
                    148930-30-7P, 2'-O-Benzyloxycarbonyltaxol
     149140-54-5P
                    149198-47-0P
                                  153652-60-9P
                                                  156294-32-5P
     156294-34-7P
                    156294-37-0P
                                   156294-38-1P
                                                  156294-39-2P
                                                  156294-43-8P
     156294-40-5P
                    156294-41-6P
                                   156294-42-7P
     156294-44-9P
                    156294-46-1P
                                   156294-47-2P
                                                  156294-48-3P
     156294-49-4P
                    156294-50-7P
                                   156294-51-8P
                                                  156406-30-3P
                    156406-32-5P
     156406-31-4P
        (prepn. and reaction of, in prepn. of fluorotaxol antitumor
        agent)
IT
     100-52-7P, Benzaldehyde, reactions
        (prepn. of)
IT
     153652-63-2P, 7.alpha.-Fluorotaxol
                                          156294-27-8P
                                                          156294-28-9P
     156294-29-0P
                    156294-30-3P
                                   156294-31-4P
                                                  156294-52-9P
     156294-53-0P
        (prepn. of, as antitumor agent)
IT
     494-47-3, Hydrofuramide 13831-31-7, Acetoxyacetyl chloride
     33069-62-4, Taxol
                         39994-75-7, L-Threonine methyl ester
     hydrochloride
                     78432-77-6, 10-Desacetyltaxol
                                                      114261-50-6,
                     115437-18-8
     Hydrothienamide
        (reaction of, in prepn. of fluorotaxol antitumor agent)
L6
                   HCA COPYRIGHT 1994 ACS
     ANSWER 2 OF 6
AN
     121:109329 HCA
ΤI
     reparation of 7,8-cyclopropataxanes as antitumor agents
IN
     Chen, Shu Hui; Farina, Vittorio
PA
     Bristol-Myers Squibb Co., USA
SO
     Eur. Pat. Appl., 35 pp.
     CODEN: EPXXDW
PΙ
     EP 577083 A1 940105
DS
         AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
ΑI
     EP 93-110375
                   930629
PRAI US 92-907261
                   920701
     US 92-995443
                   921223
     US 92-996455
                   921224
    US 93-6423 930119
     US 93-29819 930311
     US 93-62687
                  930520
DT
     Patent
```


```
LA English
IC ICM C07D305-14
ICS A61K031-335
CC 30-20 (Terpenes and Terpenoids)
Section cross-reference(s): 1
OS MARPAT 121:109329
GI
```



```
AB
     Tile compds. [I; R1 = alkanoyl, Bz, etc.; R2 = (cyclo)alkyl,
     alkenyl, aryl, etc.; R3 = H, OH, alkoxycarbonyloxy, etc.; R4 = H;
     R3R4 = 0] were prepd. Thus, 7-epi-hydroxytaxol was converted in 3
     steps to 7-deoxy-8-desmethyl-7,8-cyclopropataxol which had IC50 of
     0.183.mu.g/mL against HCT-116/VM46 human colon carcinoma cells in
     vitro.
ST
     cyclopropataxane prepn antitumor
IT
     Neoplasm inhibitors
        (cyclopropataxanes)
IT
     150799-83-0P
                    153652-63-2P
                                    156478-93-2P
                                                   156478-94-3P
        (formation of, in prepn. of antitumor agent)
IT
     105377-71-7P
                    115437-18-8P
                                    132127-34-5P
                                                   144764-08-9P
     144764-09-0P
                    144790-01-2P
                                    147650-53-1P
                                                   148121-24-8P
     148121-25-9P
                    148121-26-0P
                                    148121-28-2P
                                                   148205-41-8P
     148930-30-7P
                    148969-14-6P
                                    149140-51-2P
                                                   149140-52-3P
     149140-53-4P
                    149140-54-5P
                                    149198-47-0P
                                                   149249-91-2P
   150799-82-9P
                  153652-60-9P
                                  156294-32-5P
   156294-33-6P
                  156294-34-7P
                                  **156294-35-8P***
   156478-90-9P
                  156478-91-0P 156478-92-1P
     156557-30-1P
        (prepn. and reaction of, in prepn. of antitumor agent)
IT 150799-84-1P 156294-36-9P 156478-95-4P
   156478-96-5P
        (prepn. of, as antitumor agent)
IT
     100-52-7, Benzaldehyde, reactions
                                         32981-86-5, 10-Desacetylbaccatin
           33069-62-4, Taxol
                               39994-75-7, L-Threonine methyl ester
    hydrochloride
                     78432-77-6, 10-Deacetyltaxol 78454-17-8
     105454-04-4, 7-epi-Taxol
        (reaction of, in prepn. of antitumor agent)
```

L6 ANSWER 3 OF 6 HCA COPYRIGHT 1994 ACS

```
AN
     121:83684 HCA
     Preparation of fluorotaxols with antitumor activity
TI
     Chen, Shu Hui; Farina, Vittorio; Vyas, Dolatrai; Kant, Joydeep
IN
     Bristol-Myers Squibb Co., USA
PA
SO
     Eur. Pat. Appl., 45 pp.
     CODEN: EPXXDW
PΙ
     EP 577082 A1 940105
         AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
DS
         SE
ΑI
     EP 93-110374
                   930629
PRAI US 92-907261
                   920701
     US 92-995443
                   921223
     US 92-996455
                   921224
     US 93-6423 930119
     US 93-29819
                 930311
     US 93-62687
                  930520
DT
     Patent
     English
LA
     ICM A61K031-335
IC
     ICS
         C07D305-14
CC
     30-20 (Terpenes and Terpenoids)
     Section cross-reference(s): 1
OS
     MARPAT 121:83684
GI
```



Title compds. [I; R = (cyclo)alkyl, alkenyl, alkynyl, RxW; R1 = (cyclo)alkyl, alkenyl, alkynyl, Ph, etc.; R2 = H, OH, alkoxy(carbonyl), phenoxy(carbonyl), etc.; Rx = Ph, furyl, thienyl, naphthyl, etc.; W = bond, (CH2)1-6, alkeylene] were prepd. Thus, taxol was condensed with ClCO2CH2Ph and the product treated with DAST to give, after deprotection, I (R = R1 = Ph, R2 = OAc). I (R = Ph, R1 = OCMe3, R2 = OAc) gave mean survival of M109 lung carcinoma-implanted mice 147% that of controls at 40mg/kg i.p. on days 5 and 8 post-implant.

ST fluorotaxol prepn antitumor

IT Neoplasm inhibitors

(fluorotaxols)

IT 92-29-5P, Hydrobenzamide 132127-34-5P 133066-59-8P 144764-08-9P 144764-09-0P 144790-01-2P 147650-53-1P 148121-24-8P 148121-25-9P 148121-26-0P 148121-28-2P

```
148205-41-8P
                    148930-30-7P, 2'-O-(Benzyloxycarbonyl)taxol
     149140-54-5P
                    149198-47-0P 150799-82-9P
                 153652-60-9P
   150799-84-1P
                                 156294-32-5P
                  156294-34-7P 156294-35-8P
   156294-33-6P
   156294-36-9P
                  156294-37-0P
                                156294-38-1P
                                                156294-39-2P
     156294-40-5P
                    156294-41-6P 156294-42-7P 156294-43-8P
     56294-44-9P
                   156294-45-0P 156294-46-1P
                                                 156294-47-2P
     156294-48-3P
                    156294-49-4P
                                  156294-50-7P
                                                  156294-51-8P
     156406-29-0P
                    156406-30-3P
                                  156406-31-4P
                                                  156406-32-5P
        (prepn. and reaction of, in prepn. of antitumor agent)
IT
     153652-63-2P
                    156294-27-8P
                                   156294-28-9P
                                                 156294-29-0P
                                   156294-52-9P
     156294-30-3P
                    156294-31-4P
                                                  156294-53-0P
        (prepn. of, as antitumor agent)
IT
     98-88-4, Benzoyl chloride
                                 100-52-7, Benzaldehyde, reactions
                             13831-31-7, Acetoxyacetyl chloride
     494-47-3, Hydrofuramide
     33069-62-4, Taxol
                        39994-75-7, L-Threonine methyl ester
     hydrochloride
                    78432-77-6, 10-Desacetyltaxol
                                                     114261-50-6
     115437-18-8
        (reaction of, in prepn. of antitumor agent)
     ANSWER 4 OF 6 HCA COPYRIGHT 1994 ACS
L6
AN
     120:299016 HCA
ΤI
     Synthesis of Ring B-Rearranged Taxane Analogs
     Klein, Larry L.; Maring, Clarence J.; Li, Leping; Yeung, Clinton M.;
AU
     Thomas, Sheela A.; Grampovnik, David J.; Plattner, J. J.; Henry,
     Rodger F.
     Anti-Infective Division, Abbott Laboratories, Abbott Park, IL,
CS
     60064, USA
     J. Org. Chem. (1994), 59(9), 2370-3
SO
     CODEN: JOCEAH; ISSN: 0022-3263
DT
     Journal
LA
     English
CC
     30-20 (Terpenes and Terpenoids)
     Section cross-reference(s): 1, 75
os
     CASREACT 120:299016; CJACS-IMAGE; CJACS
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Reaction of the C-7 hydroxyl group on the 9-dihydrotaxane skeleton, e.g. I, with triflic anhydride causes a major skeletal rearrangement to occur leading to contraction of ring B. A side product, II, is the formation of a ring C-fused cyclopropane structure. The requisite C-13 phenylisoserinate side chains are appended via an initial deacylation of the C-13 acetate followed by reacylation and deprotection. These rearranged compds., e.g. III (R = Bz, CO2CMe3) and IV show very similar structural features with the parent 9-dihydrotaxane skeleton and also retain biol. activity.
- ST taxane diterpene rearranged analog biol activity; dihydrotaxane skeleton rearrangement triflic anhydride; ring contraction dihydrotaxane skeleton; cyclopropanation dihydrotaxane skeleton triflic anhydride; phenylisoserinate deriv acylation baccatin analog IT Crystal structure
 - (of baccatin III rearranged analogs)

GI

426

```
IT
     Rearrangement
        (of dihydrotaxane skeleton with triflic anhydride)
     Neoplasm inhibitors
IT
        (taxol rearranged analogs)
IT
     Diterpenes and Diterpenoids
        (taxane, rearranged analogs, prepn. and antitumor activity of)
IT
     133066-61-2
                   152089-12-8
        (acylation by, of baccatin III rearranged analogs)
IT
     27548-93-2DP, Baccatin III, analogs
        (prepn. and acylation of, with azetidinones taxol analogs from)
IT
     154854-31-6P
        (prepn. and acylation of, with azetidinones, taxol analogs from)
     33069-62-4DP, analogs 148584-53-6DP, 9-Dihydrotaxol, analogs
IT
     154854-32-7P 154854-37-2P
                                 154854-38-3P
        (prepn. and antitumor activity of)
IT
     154854-36-1P
        (prepn. and attempted acylation of, with azetidinones)
IT
     154854-33-8P
                    154854-39-4P
        (prepn. and rearrangement of, with triflic anhydride)
IT
     154854-30-5P
        (prepn. and reductive deacetylation of, in synthesis of taxol
        analogs)
IT 154854-34-9P
        (prepn. and regioselective deacetylation of, in synthesis of
        taxol analogs)
IT 154854-35-0P
        (prepn. and silylation of, in synthesis of taxol analogs)
     142203-65-4, 13-Acetyl-9-dihydrobaccatin III
IT
        (rearrangement of, with triflic anhydride)
     ANSWER 5 OF 6 HCA COPYRIGHT 1994 ACS
L6
AN
     120:218230 HCA
     On the reaction of taxol with DAST
TI
ΑU
     Chen, Shu Hui; Huang, Stella; Farina, Vittorio
CS
     Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492-7660,
     USA
SO
     Tetrahedron Lett. (1994), 35(1), 41-4
     CODEN: TELEAY; ISSN: 0040-4039
DT
     Journal
     English
LA
CC
     30-20 (Terpenes and Terpenoids)
     Section cross-reference(s): 1
os
     CASREACT 120:218230
GΙ
```

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- Treatment of 2'-Cbz-taxol (I) with DAST yields several interesting new products, including 7-.alpha.-fluoro deriv. II (R = CO2CH2Ph) and a cyclopropane-contg. product, III (R = CO2CH2Ph). II (R = H) and III (R = H) showed excellent ability to polymerize tubulins in vitro and displayed potent toxicity vs HCT-116 (no data).
- ST txol reaction DAST diethyaminosulfur trifluoride
- IT Fluorination

```
Rearrangement
        (in reaction of taxol and drivs. with DAST)
IT
     Tubulins
        (taxol deriv. polymn. promoter)
IT
     Neoplasm inhibitors
        (taxol derivs. (no data))
IT
     7782-41-4
        (fluorination, in reaction of taxol and drivs. with DAST)
                  150799-83-0P
                                 153652-60-9P
                                                 153652-61-0P
IT 150799-82-9P
        (prepn. of, by reaction of taxol deriv. with DAST)
IT
     153652-62-1P
        (prepn. of, by reaction of taxol with DAST)
IT
     153652-64-3P 153652-65-4P
        (prepn. of, via reaction of taxol deriv. with DAST)
                  153652-63-2P
IT 150799-84-1P
        (prepn., tubulin polymn., and cytotoxicity of)
IT
                  148930-30-7
     33069-62-4
        (reactant, reaction of taxol and derivs. with DAST)
IT
     38078-09-0, DAST
        (reagent, reaction of taxol and derivs. with DAST)
     ANSWER 6 OF 6 HCA COPYRIGHT 1994 ACS
L6
AN
     119:226216 HCA
     Serendipitous synthesis of a cyclopropane-containing taxol analog
TI
     via anchimeric participation of an unactivated angular methyl group
     Chen, Shu Hui; Huang, Stella; Wei, Jianmei; Farina, Vittorio
ΑU
     Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492-7660,
CS
SO
     J. Org. Chem. (1993), 58(17), 4520-1
     CODEN: JOCEAH; ISSN: 0022-3263
DT
     Journal
LA
     English
CC
     30-20 (Terpenes and Terpenoids)
     Section cross-reference(s): 1
     CASREACT 119:226216; CJACS-IMAGE; CJACS
os
GΙ
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Treatment of a 7-epi-taxol deriv. I with DAST in dichloromethane led to an unexpected reaction, involving participation of the C(19)-Me group and clean formation of a cyclopropane ring. A subsequent reaction leading to A ring contraction to cyclopentene II was also obsd., but this was controlled by careful monitoring of the reaction and by introducing a limited amt. of the reagent. The analog of taxol thus produced, III, was shown to retain a high degree of biol. activity.
- ST epitaxol cyclopropanation ring contraction DAST; taxol analog prepn biol activity
- IT Ring contraction (cyclopropanation and, during fluorination of epitaxol deriv. by ethylaminosulfur trifluoride)

628

 IT Neighboring group participation (in cyclopropanation of epitaxol deriv. with diethylaminosulfur trifluoride)

TI Fluorination

(of epitaxol deriv. with DAST, cyclopropanation and ring contraction during)

IT Ring closure and formation

(cyclopropanation, ring contraction and, during fluorination of epitaxol deriv. with diethylaminosulfur trifluoride)

IT148969-14-6

> (attempted fluorination of, with diethylaminosulfur trifluoride, cyclopropanation and ring contraction during)

IT 7782-41-4

> (fluorination, of epitaxol deriv. with DAST, cyclopropanation and ring contraction during)

33069-62-4DP, deoxyanalogs 150799-84-1P IT (prepn. and antitumor activity of)

IT 150799-82-9P

(prepn. and hydrogenolasis of)

IT 150799-83-0P (prepn. of)

12 hit RN's from the 6 sel hit rn 16 1-6 E1 THROUGH E12 ASSIGNED

=> file capre FILE 'CAPREVIEWS' ENTERED AT 15:57:33 ON 09 DEC 94 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1994 American Chemical Society (ACS)

FILE COVERS CURRENT RECORDS AND IS UPDATED DAILY 8 DEC 1994 (941208/ED) FILE LAST UPDATED:

Some records may not contain a volume, issue, and page number, because they are from advance abstracts of articles accepted for publication in journals published by the ACS. These abstracts will appear first in Advance ACS Abstracts. Please enter HELP ACSJOURNALS to see a list of the advance ACS journal titles.

To help control your online searching costs, consider using the HCAPREVIEWS File when using the FSEARCH command or when conducting SmartSELECT searches with large numbers of terms.

=> d his 17

L7

(FILE 'CAPREVIEWS' ENTERED AT 15:52:39 ON 05 DEC.,

2 S L5
SET COST OFF 2 Ca preview ref a from

FILE 'REGISTRY' ENTERED AT 15:53:46 ON 09 DEC 94 the structure

SEARCH

SEL HIT RN L6 1-6

FILE 'CAPREVIEWS' ENTERED AT 15:57:33 ON 09 DEC 94

```
=> d 17 1-2 all
     ANSWER 1 OF 2 CApreviews COPYRIGHT 1994 ACS
L7
AN
     94:609329 CApreviews
ΤI
     New taxoids, their preparation, and pharmaceutical compositions
     containing them
     Bouchard, Herve; Bourzat, Jean-Dominique; Commercon, Alain
IN
PA
     Rhone Poulenc Rorer SA, Fr.
SO
     Fr. Demande, 35 pp.
     CODEN: FRXXBL
PI
     FR 2698871 A1
                   940610
AΙ
     FR 92-14813 921209
DT
     Patent
LA
     French
IC
     ICM C07D305-14
     ICS A61K031-335
CC
     30 (Terpenes and Terpenoids)
     Section cross-reference(s): 1
     Taxoids I [R = H, Ac; R1 = Bz, R2OCO; R2 = alkyl, alkenyl, alkynyl,
AB
     cycloalkyl, cycloalkenyl, bicycloalkyl, Ph, heterocyclyl; Ar = aryl]
     were prepd. (1 example) for use as antitumor agents and
     antineoplastics, esp. for ovarian cancer. Thus, protected taxotere
     deriv. II (BOC = Me3COCO; R7 = R10 = CO2CH2CCl3) was deprotected by
     powd. Zn in AcOH-EtOAc mixt. to give II (R7 = R10 = H), which was
     treated with (CF3SO2)20 and pyridine in CH2Cl2 to give II (R7 =
     SO2CF3, R10 = H).
                        The latter was treated with NaN3 in MeCN-THF
     mixt. and heated to 80.degree., which induced cyclization of the
     triflate to the 7.beta., 8.beta.-methylene deriv. Subsequent
     cleavage of the oxazolidine protective function in formic acid and
     replacement of the BOC group with di-tert-Bu dicarbonate gave final
     product I (R = H, R1 = BOC, Ar = Ph). Compds. I are said to be at
     least as active as taxol and taxotere, and were active at 1-10 mg/kg
     i.p. against melanoma B16 in mice (no addnl. data).
     RN LIST MAY NOT BE COMPLETE: 358-23-6;
IT
                                             24424-99-5;
                                                          143527-76-8;
   158811-30-4; 159262-90-5;
                               159262-91-6;
     159262-92-7; 159262-93-8
L7
     ANSWER 2 OF 2
                   CApreviews
                               COPYRIGHT 1994 ACS
     94:392956 CApreviews
AN
     Preparation of 7-halo- and 7.beta., 8.beta.-methanotaxols, their
TI
     antineoplastic use and pharmaceutical composition containing them
IN
     Hester, Jackson B., Jr.; Johnson, Roy A.; Kelly, Robert C.; Midy,
     Eldon G.; Skulnick, Harvey I.
PA
     Upjohn Co., USA
     PCT Int. Appl., 127 pp.
SO
     CODEN: PIXXD2
PΙ
     WO 9413655 A1 940623
         AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP,
DS
         KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU,
         SD, SE, SK, UA, US, US, US, US, UZ, VN
    RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
```

BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

ΑI

WO 93-US11827

US 93-13826 930202

PRAI US 92-990579

931213

921215

```
US 93-76337
                  930611
     US 93-122974
                   930917
DT
     Patent
LA
     English
IC
     ICM
          C07D305-14
          C07D413-12; C07D263-04
     30 (Terpenes and Terpenoids)
CC
     Section cross-reference(s): 1, 34, 63
     This invention provides 7-deoxy-taxol analogs or formula (I).
AB
     compds. of formula (I) (including formulate II and III) are useful
     for the same cancers for which taxol has been shown active,
     including human ovarian cancer, breast cancer, and malignant
     melamoma as well as lung cacer, gastric cancer, colon cancer, head
     and neck cancer, and leukemia.
IT
     RN LIST MAY NOT BE COMPLETE: 77-74-7;
                                             103-71-9;
                                                         501-53-1;
     558-42-9;
                590-42-1;
                            1609-86-5; 2094-72-6; 2890-61-1;
                                                                 3282-30-2;
     7693-46-1;
                 17341-93-4;
                               17380-62-0;
                                             22509-74-6;
                                                          27548-93-2;
                  32981-86-5;
                                              78432-77-6; 91352-76-0;
     32981-85-4;
                                33069-62-4;
     95603-44-4;
                  99458-15-8;
                               100431-55-8;
                                             103150-33-0;
                                                             114915-13-8;
     114915-14-9;
                   114977-28-5;
                                  115437-21-3;
                                                 124605-42-1;
                                                               125354-16-7;
     133524-70-6;
                   150799-84-1;
                                  153652-63-2;
                                                 155399-27-2;
     155399-30-7;
                   156294-33-6;
                                  156294-36-9;
                   157580-27-3;
                                  157580-31-9;
     157240-36-3;
                                                 158809-53-1;
   158809-54-2; 158809-55-3; 158809-56-4;
     158809-57-5; 158809-58-6;
                                  158809-59-7;
                                                 158809-61-1;
     158809-62-2;
                   158809-63-3;
                                  158809-64-4;
                                                 158809-65-5;
                                                                158809-66-6;
     158809-67-7;
                   158809-68-8;
                                  158809-69-9;
                                                 158809-70-2;
                                                                158809-71-3;
     158809-72-4;
                   158809-73-5;
                                  158809-74-6;
                                                 158809-75-7;
                                                                158809-76-8;
     158809-77-9;
                   158809-78-0;
                                  158809-79-1;
                                                 158809-80-4;
                                                               158809-81-5;
     158809-82-6;
                   158809-83-7;
                                  158809-84-8;
   158809-85-9; 158809-86-0;
                                158809-87-1;
   158809-89-3;
                 158809-90-6;
                                158809-91-7;
   158809-92-8;
                 158809-93-9;
                                158809-94-0;
   158809-95-1;
                 158809-96-2;
                                158809-97-3;
   158809-98-4;
                 158809-99-5;
                                158810-00-5;
   158810-01-6;
                 158810-02-7;
                                158810-03-8;
   158810-04-9;
                 158810-05-0;
                                158810-06-1;
   158810-07-2;
                 158810-08-3;
                                158810-09-4;
   158810-10-7;
                 158810-11-8;
                                158810-12-9;
     158810-13-0;
                                                 158810-16-3;
                   158810-14-1;
                                  158810-15-2;
                                                               158810-17-4;
     158810-18-5;
                   158810-19-6;
                                  158810-20-9;
   158810-21-0;
                 158810-22-1;
                                158810-23-2;
   158810-24-3;
                 158810-25-4;
                                158810-26-5;
   158810-27-6;
                 158810-28-7;
                                158810-29-8;
   158810-30-1;
                 158810-31-2;
                                158810-32-3;
     158810-33-4;
                   158810-34-5;
                                  158810-35-6;
                                                 158810-36-7;
                                                               158810-37-8;
     158810-38-9;
                   158810-39-0;
                                  158810-40-3;
                                                 158810-41-4;
                                                               158810-42-5;
     158810-43-6;
                   158810-44-7;
                                                 158810-46-9;
                                                               158810-47-0;
                                  158810-45-8;
     158810-48-1;
                   158810-49-2;
                                  158810-50-5;
                                                 158810-51-6;
                                                               158810-52-7;
     158810-53-8;
                   158810-54-9;
                                  158810-55-0;
                                                 158810-56-1;
                                                               158810-57-2;
     158810-58-3;
                   158810-59-4;
                                  158810-60-7;
                                                 158810-61-8;
                                                               158810-62-9;
     158810-63-0;
                   158810-64-1;
                                  158810-65-2;
                                                 158810-66-3;
                                                               158810-67-4;
     158810-68-5;
                   158810-69-6;
                                  158810-70-9;
                                                               158810-72-1;
                                                 158810-71-0;
     158810-73-2;
                   158810-74-3;
                                  158810-75-4;
                                                 158810-76-5;
                                                               158810-77-6;
     158810-78-7;
                   158810-79-8;
                                  158810-80-1;
                                                 158810-81-2;
                                                               158810-82-3;
     158810-83-4;
                   158810-84-5;
                                  158810-85-6;
                                                 158810-86-7;
                 158810-88-9;
                                158810-89-0;
  158810-87-8;
```

```
158810-93-6;
                                                              158810-94-7;
     158810-90-3;
                   158810-91-4;
                                 158810-92-5;
     158810-95-8;
                   158810-96-9;
                                 158810-97-0;
                                               158810-98-1;
                                                              158810-99-2;
                                                              158811-04-2;
     158811-00-8;
                   158811-01-9;
                                 158811-02-0;
                                               158811-03-1;
     158811-05-3;
                   158811-06-4;
                                 158811-07-5;
                                               158811-08-6;
                                                              158811-09-7;
     158811-10-0;
                   158811-11-1;
                                 158811-12-2;
                                               158811-13-3;
                                                              158811-14-4;
     158811-15-5;
                   158811-16-6;
                                 158811-17-7;
                                               158811-18-8;
                                                              158811-19-9;
     158811-20-2;
                   158811-21-3;
                                 158811-22-4;
                                               158811-23-5;
                                               158811-27-9;
     158811-24-6;
                   158811-25-7;
                                 158811-26-8;
   158811-28-0; 158811-29-1; 158811-30-4;
   158811-31-5;
                 158811-32-6;
                               158811-33-7;
   158811-34-8;
                 158811-35-9;
                               158811-36-0;
                 158811-38-2;
   158811-37-1;
                               158811-39-3;
   158811-40-6;
                 158811-41-7;
                               158811-42-8;
   158811-43-9; 158811-44-0;
                               158811-45-1;
   158811-46-2;
                 158811-47-3;
                               158811-48-4;
   158811-49-5;
                 158811-50-8;
                               158811-51-9;
   158811-52-0; 158851-40-2;
                               158851-41-3;
                                            158851-42-4;
     158851-43-5;
                   158851-44-6;
                                 158851-45-7;
                                               158851-47-9;
                                                             158851-48-0;
     158851-49-1;
                   158851-50-4;
                                 158851-51-5;
                                               158851-52-6;
                                                              158851-53-7;
     158851-54-8;
                   158851-55-9;
                                                              158851-58-2;
                                 158851-56-0;
                                               158851-57-1;
                                               158851-60-6;
IT
    RN LIST MAY NOT BE COMPLETE: 158851-59-3;
     158851-61-7; 158851-62-8;
                                 158851-63-9;
                                               158851-64-0;
                                                              158851-65-1;
                   158851-67-3;
                                 158851-69-5;
     158851-66-2;
                                               158851-70-8;
                                                              158851-71-9;
                                158851-74-2;
     158851-72-0; 158851-73-1;
                                               158851-75-3;
                                                             158851-76-4;
     158851-77-5; 158851-78-6;
                                                             158851-81-1;
                                 158851-79-7;
                                               158851-80-0;
                   158851-83-3;
     158851-82-2;
                                 158851-84-4;
                                               158851-85-5;
                                                             158851-86-6;
     158851-87-7;
                   158851-88-8;
                                 158851-89-9;
                                               158851-90-2;
                   158851-92-4;
                                 158851-93-5;
     158851-91-3;
                                               158851-94-6;
   158851-95-7
                            hit RN's from these 2 Caprevu
```

sel hit rn 1-2 17 E13 THROUGH E92 ASSIGNED

=> file req FILE 'REGISTRY' ENTERED AT 15:58:57 ON 09 DEC 94 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1994 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 02 DEC 94 HIGHEST RN 159344-42-0 DICTIONARY FILE UPDATES: 08 DEC 94 HIGHEST RN 159344-42-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 1994

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
=> s e1-e12
```

```
1 150799-82-9/BI
    (150799-82-9/RN)
1 150799-84-1/BI
    (150799-84-1/RN)
1 156294-33-6/BI
    (156294-33-6/RN)
1 156294-35-8/BI
    (156294-35-8/RN)
1 156294-36-9/BI
    (156294-36-9/RN)
```

1 154854-34-9/BI

(154854-34-9/RN)

1 154854-35-0/BI

(154854-35-0/RN)

1 154854-37-2/BI

(154854-37-2/RN)

1 156478-90-9/BI

(156478-90-9/RN)

1 156478-92-1/BI

(156478-92-1/RN)

1 156478-95-4/BI

(156478-95-4/RN)

1 156478-96-5/BI

(156478-96-5/RN)

12 (150799-82-9/BI OR 150799-84-1/BI OR 156294-33-6/BI OR 156 294-35-8/BI OR 156294-36-9/BI OR 154854-34-9/BI OR 154854-35-0/BI OR 154854-37-2/BI OR 156478-90-9/BI OR 156478-92-1 /BI OR 156478-95-4/BI OR 156478-96-5/BI)

=> d 18 1-12 ide can

copyright 1994 ACS from the

L8 ANSWER 1 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN **156478-96-5** REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
12a-(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12bdodecahydro-2-hydroxy-5,13,13-trimethyl-7,8-dioxo-2,6-methano-2Hcyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester,
[1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R*),8aS*,9a.alpha.,1
0a.alpha.,12a.alpha.,12b.alpha.]]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, benzenepropanoic acid deriv. (9CI)

MF C45 H45 N O12

SR CA

L8

LC STN Files: CA

DES *

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109329

L8 ANSWER 2 OF 12 REGISTRY COPYRIGHT 1994 ACS RN 156478-95-4 REGISTRY Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, CN 12a-(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12bdodecahydro-2,7-dihydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2Hcyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester, [1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R*),7.beta.,8aS*,9a. alpha.,10a.alpha.,12a.alpha.,12b.alpha.]]- (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, CN benzenepropanoic acid deriv. (9CI) MF C45 H47 N O12 SR CA STN Files: LC CA

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109329

L8 ANSWER 3 OF 12 REGISTRY COPYRIGHT 1994 ACS RN **156478-92-1** REGISTRY CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-[[(2propenyloxy)carbonyl]oxy]-, 12a-(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13trimethyl-7,8-dioxo-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz [1,2-b]oxet-4-yl ester, [1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.b eta.R*),8aS*,9a.alpha.,10a.alpha.,12a.alpha.,12b.alpha.]]- (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, CN benzenepropanoic acid deriv. (9CI) MF C49 H49 N O14

SR CA

LC STN Files: CA

DES *

DES

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109329

L8 ANSWER 4 OF 12 REGISTRY COPYRIGHT 1994 ACS RN **156478-90-9** REGISTRY CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-[[(2,2,2trichloroethoxy)carbonyl]oxy]-, 12a-(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13trimethyl-8-oxo-7-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester, [1S-[1.alpha., 2.alpha., 4.alpha.(.alpha.S*,.beta.R*), 7.beta., 8aS*, 9a. alpha., 10a.alpha., 12a.alpha., 12b.alpha.]] - (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, CN benzenepropanoic acid deriv. (9CI) MF C51 H49 Cl6 N O16 SR CA LC STN Files: CA DES

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109329

L8 ANSWER 5 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN 156294-36-9 REGISTRY

CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, 7,12a-bis(acetyloxy)-1-(benzoyloxy)1,3,4,7,8,9,9a,10,10a,12,12a,12b-docecahydro-2-hydroxy-5,13,13trimethyl-8-oxo-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester, [1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R
),7.beta.,8aS,9a.alpha.,10a.alpha.,12a.alpha.,12b.alpha.]]- (9CI)
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, benzenepropanoic acid deriv. (9CI)

MF C45 H53 N O14

SR CA

LC STN Files: CA, CAPREVIEWS

DES *

- 1 REFERENCES IN FILE CAPREVIEWS
- 3 REFERENCES IN FILE CA (1967 TO DATE)

434

REFERENCE 1: P 121:109331

REFERENCE 2: P 121:109329

REFERENCE 3: P 121:83684

L8 ANSWER 6 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN 156294-35-8 REGISTRY

CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-.alpha.-[(triethylsilyl)oxy]-, 7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-docecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester, [1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R*),7.beta.,8aS*,9a.alpha.,10a.alpha.,12a.alpha.,12b.alpha.]]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, benzenepropanoic acid deriv. (9CI)

MF C51 H67 N O14 Si

SR CA

LC STN Files: CA

DES *

3 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109331

REFERENCE 2: P 121:109329

REFERENCE 3: P 121:83684

L8 ANSWER 7 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN 156294-33-6 REGISTRY

CN 2,6-Methano-8H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-8-one,
7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,2,3,4,7,9,9a,10,10a,12,12a,12bdodecahydro-2,4-dihydroxy-5,13,13-trimethyl-, [1S(1.alpha.,2.alpha.,4.alpha.,7.beta.,8aS*,9a.alpha.,10a.alpha.,12a.al
pha.,12b.alpha.)]- (9CI) (CA INDEX NAME)

MF C31 H36 O10

SR CA

LC STN Files: CA, CAPREVIEWS DES *

OH Me OH Me OAC OAC

1 REFERENCES IN FILE CAPREVIEWS

3 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109331

REFERENCE 2: P 121:109329

REFERENCE 3: P 121:83684

L8 ANSWER 8 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN 154854-37-2 REGISTRY

CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, 7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2,8-dihydroxy-5,13,13-trimethyl-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester, [1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R*),7.beta.,8.alpha.,8aS*,9a.alpha.,10a.alpha.,12a.alpha.,12b.alpha.] - (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, benzenepropanoic acid deriv. (9CI)

MF C45 H55 N O14

SR CA

LC STN Files: CA, CASREACT

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: 120:299016

L8 ANSWER 9 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN **154854-35-0** REGISTRY

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete1,2,4,7,8,12a(12H)-hexol, 1,3,4,7,8,9,9a,10,10a,12b-decahydro5,13,13-trimethyl-, 7,12a-diacetate 1-benzoate, [1S(1.alpha.,2.alpha.,4.alpha.,7.beta.,8.alpha.,8aS*,9a.alpha.,10a.alph
a.,12a.alpha.,12b.alpha.)]- (9CI) (CA INDEX NAME)

MF C31 H38 O10

SR CA

LC STN Files: CA, CASREACT

DES *

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: 120:299016

L8 ANSWER 10 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN **154854-34-9** REGISTRY

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete1,2,4,7,8,12a(12H)-hexol, 1,3,4,7,8,9,9a,10,10a,12b-decahydro5,13,13-trimethyl-, 4,7,12a-triacetate 1-benzoate,
[1S-(1.alpha.,2.alpha.,4.alpha.,7.beta.,8.alpha.,8aS*,9a.alpha.,10a.
alpha.,12a.alph.,12b.alpha.)]- (9CI) (CA INDEX NAME)

```
MF C33 H40 O11
SR CA
```

LC STN Files: CA, CASREACT

DES *

1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: 120:299016

L8 ANSWER 11 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN 150799-84-1 REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12bdodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2Hcyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester,
[1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R*),7.beta.,8aS*,9a.

alpha.,10a.alpha.,12a.alpha.,12b.alpha.]]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, benzenepropanoic acid deriv. (9CI)

MF C47 H49 N O13

SR CA

LC STN Files: CA, CAPREVIEWS, CASREACT

DES *

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CAPREVIEWS

4 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109331

REFERENCE 2: P 121:109329

REFERENCE 3: 120:218230

REFERENCE 4: 119:226216

L8 ANSWER 12 OF 12 REGISTRY COPYRIGHT 1994 ACS

RN 150799-82-9 REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.[[(phenylmethoxy)carbonyl]oxy]-, 7,12a-bis(acetyloxy)-1-(benzoyloxy)1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13trimethyl-8-oxo-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-

b]oxet-4-yl ester, [1S-[1.alpha.,2.alpha.,4.alpha.(.alpha.S*,.beta.R
),7.beta.,8aS,9a.alpha.,10a.alpha.,12a.alpha.,12b.alpha.]]- (9CI)
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,6-Methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxete, benzenepropanoic acid deriv. (9CI)

MF C55 H55 N O15

SR CA

LC STN Files: CA, CASREACT, CHEMINFORMRX

DES *

4 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P 121:109331

REFERENCE 2: P 121:109329

REFERENCE 3: 120:218230

REFERENCE 4: 119:226216

=> d his 18-

(FILE 'CAPREVIEWS' ENTERED AT 15:52:39 ON 09 DEC 94)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 15:53:46 ON 09 DEC 94

FILE 'HCA' ENTERED AT 15:55:33 ON 09 DEC 94 SEL HIT RN L6 1-6

FILE 'CAPREVIEWS' ENTERED AT 15:57:33 ON 09 DEC 94 SEL HIT RN 1-2 L7

FILE 'REGISTRY' ENTERED AT 15:58:57 ON 09 DEC 94

L8 12 S E1-E12

L9 80 S E13-E92

L10 77 S L9 NOT L8

=> d l10 1, 10,20,30,40,50,60,70,75,77 ide can

L10 ANSWER 1 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN 159262-91-6 REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C46 H55 N O13

SR CA

LC STN Files: CAPREVIEWS

DES *

Structures from the. 2 Capreview ref's

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 10 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN **158811-48-4** REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C47 H47 Cl F N O13

SR CA

LC STN Files: CAPREVIEWS

PAGE 1-A

PAGE 2-A

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 20 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN **158811-38-2** REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C51 H57 N O13

SR CA

LC STN Files: CAPREVIEWS

PAGE 1-A

PAGE 2-A

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 30 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN **158811-28-0** REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C52 H56 N2 O16

SR CA

LC STN Files: CAPREVIEWS

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 40 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN 158810-27-6 REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C48 H49 N O15

SR CA

LC STN Files: CAPREVIEWS

DES *

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 50 OF 77 REGISTRY COPYRIGHT 1994 ACS RN 158810-09-4 REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C46 H55 N O14

SR CA

LC STN Files: CAPREVIEWS

DES *

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 60 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN **158809-99-5** REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C49 H52 N2 O14

SR CA

LC STN Files: CAPREVIEWS

DES *

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 70 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN **158809-89-3** REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C50 H54 N2 O14 . C H2 O2

SR CA

STN Files: CAPREVIEWS LC

> CM 1

CRN 158809-88-2 CMF C50 H54 N2 O14

CDES *

CM2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 75 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN **158809-58-6** REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MFC45 H54 N2 O13

SR CA

LCSTN Files: CAPREVIEWS

DES

1 REFERENCES IN FILE CAPREVIEWS

L10 ANSWER 77 OF 77 REGISTRY COPYRIGHT 1994 ACS

RN 158809-54-2 REGISTRY

CN INDEX NAME NOT YET ASSIGNED

MF C50 H50 Cl3 N O15

SR CA

LC STN Files: CAPREVIEWS

DES *

1 REFERENCES IN FILE CAPREVIEWS

=> file home FILE 'HOME' ENTERED AT 16:02:51 ON 09 DEC 94